BLA 761181 · Regeneron Pharmaceuticals
Evkeeza
Evinacumab-Dgnb · Injection
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Feb 11, 2021: To treat homozygous familial hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Feb 11, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
12
4 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat homozygous familial hypercholesterolemia
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 25, 2025 Supplement 2 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Mar 21, 2023 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- Feb 11, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
- EVKEEZA · EVINACUMAB-DGNB 345MG/2.3ML · SOLUTION, INJECTION · Prescription
- EVKEEZA · EVINACUMAB-DGNB 1200MG/8ML · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Evinacumab" as an intervention, any sponsor and status, largest first.
- Study of Evinacumab (REGN1500) in Participants With Persistent HypercholesterolemiaPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03175367 · 272 participants · Start Nov 10, 2017 · Primary completion May 22, 2020
Drug: Evinacumab; Matching placebo · For: Hypercholesterolemia
Sites: Los Angeles, California; Newport Beach, California; Boca Raton, Florida · 95 sites in all
- Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney DiseasePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07271186 · 195 participants (planned) · Start Jan 9, 2026 · Primary completion Oct 13, 2028
Drug: ALN-ANG3; Evinacumab and 1 more · For: Diabetic Kidney Disease (DKD)
Sites: Huntsville, Alabama; Little Rock, Arkansas; Huntington Beach, California · 59 sites in all
- Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03409744 · 116 participants · Start Mar 13, 2018 · Primary completion Apr 13, 2023
Drug: evinacumab · For: Homozygous Familial Hypercholesterolemia
Sites: Los Angeles, California; Boca Raton, Florida; Boston, Massachusetts · 38 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT01749878 · 99 participants · Start Dec 2012 · Primary completion Jan 2016
Drug: REGN1500; placebo · For: Hypertriglyceridemia
Sites: Philadelphia, Pennsylvania; Dallas, Texas
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03146416 · 96 participants · Start May 16, 2017 · Primary completion Jun 14, 2018
Drug: Evinacumab; Placebo · For: Healthy Volunteers
Sites: Cypress, California
- Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03399786 · 65 participants · Start Jan 18, 2018 · Primary completion Jun 10, 2019
Drug: evinacumab; Placebo · For: Homozygous Familial Hypercholesterolemia
Sites: Boca Raton, Florida; Boston, Massachusetts; New York, New York · 30 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02107872 · 55 participants · Start Apr 2014 · Primary completion Sep 2015
Drug: REGN1500; placebo · For: Metabolic Disorders
Sites: Daytona Beach, Florida; Evansville, Indiana; Dallas, Texas · 4 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03452228 · 52 participants · Start Jun 7, 2018 · Primary completion Dec 17, 2019
Drug: evinacumab; Placebo · For: Severe Hypertriglyceridemia (sHTG)
Sites: Boca Raton, Florida; Atlanta, Georgia; Kansas City, Kansas · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Evkeeza (Evinacumab-Dgnb)
2024 spending
$10.8M
Beneficiaries
27
245 claims
Per beneficiary
$400,140
$5,383.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $777,909 |
| 2022 | $3,474,160 |
| 2023 | $6,739,753 |
| 2024 | $10,803,789 |
Part B: Evkeeza (Evinacumab-Dgnb) · HCPCS J1305
2024 spending
$21.8M
Beneficiaries
63
541 claims
Per beneficiary
$346,737
2024 ASP limit $181.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $400,316 |
| 2022 | $4,166,459 |
| 2023 | $10,904,082 |
| 2024 | $21,844,436 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ, Rosenson RS, Reeskamp LF, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
Gaudet D, Greber-Platzer S, Reeskamp LF, et al. · Eur Heart J 2024 · Clinical Trial, Phase III, Multicenter Study
- Evinacumab in Patients with Refractory Hypercholesterolemia.
Rosenson RS, Burgess LJ, Ebenbichler CF, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Multicenter Study
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE, Gusarova V, Dunbar RL, et al. · N Engl J Med 2017 · Clinical Trial, Phase I, Randomized Controlled Trial
- Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study.
Iannuzzo G, Calcaterra I, Gentile M, et al. · Adv Ther 2025 · Clinical Trial, Phase III, Multicenter Study
- Umbrella Review on Non-Statin Lipid-Lowering Therapy.
Beshir SA, Hussain N, Elnor AA, et al. · J Cardiovasc Pharmacol Ther 2021 · Systematic Review
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.